Seranova Bio
Seranova Bio is a biotechnology company founded in 2021 and headquartered in South San Francisco, CA. It specializes in discovering and developing first-in-class therapeutics inspired by patients' protective autoantibodies using its proprietary REAP (Rapid Exoproteome Antigen Profiling) technology platform. REAP enables the detection of functional autoantibody reactivities against the human exoproteome at unprecedented scale and sensitivity by using genetically barcoded yeast displaying correctly folded proteins. Seranova combines this high-quality autoantibody data with clinical information through its Seravista machine learning platform to identify causal autoantibodies and promising therapeutic targets. The company focuses on diseases such as autoimmunity, cancer, and neurodegeneration, leveraging natural clinical trials where patients develop protective autoantibodies. Seranova's business model is primarily based on developing therapeutics and collaborating with partners. The company is backed by investors including Foresite Capital and led by founder Aaron Ring, MD, PhD, an immunobiology professor at Yale and experienced biotech entrepreneur.
Seranova Bio
Seranova Bio is a biotechnology company founded in 2021 and headquartered in South San Francisco, CA. It specializes in discovering and developing first-in-class therapeutics inspired by patients' protective autoantibodies using its proprietary REAP (Rapid Exoproteome Antigen Profiling) technology platform. REAP enables the detection of functional autoantibody reactivities against the human exoproteome at unprecedented scale and sensitivity by using genetically barcoded yeast displaying correctly folded proteins. Seranova combines this high-quality autoantibody data with clinical information through its Seravista machine learning platform to identify causal autoantibodies and promising therapeutic targets. The company focuses on diseases such as autoimmunity, cancer, and neurodegeneration, leveraging natural clinical trials where patients develop protective autoantibodies. Seranova's business model is primarily based on developing therapeutics and collaborating with partners. The company is backed by investors including Foresite Capital and led by founder Aaron Ring, MD, PhD, an immunobiology professor at Yale and experienced biotech entrepreneur.